Latest News

The agreement brings together Lilly’s expertise in developing innovative medicines with Abu Dhabi’s advanced healthcare infrastructure, population-scale health data, and genomics capabilities.

The initiative has strengthened disease prevention, maternal healthcare services, laboratory capacity, and surveillance systems, helping the territory maintain high standards of care.

The new site will serve as the company’s U.S. global headquarters and future manufacturing centre as it accelerates the development of targeted cancer therapies.

Unlike conventional sequencing technologies, Axelios 1 uses SBX chemistry to convert DNA or RNA molecules into enlarged surrogate polymers known as Xpandomers.

Unlike previous Ebola epidemics caused by the Zaire strain, the current Bundibugyo outbreak has no licensed vaccine or approved treatment, making research an urgent public health priority.

Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.

The new committee will serve as the highest oversight body for implementing the action plan by providing strategic leadership, policy direction and inter-agency coordination.

The centre will treat patients with a broad range of conditions, including stroke, spinal cord injuries, traumatic brain injuries, multiple sclerosis, cerebral palsy, autism spectrum disorder, muscular dystrophy, motor neuron disease, movement disorders, Alzheimer’s disease, dementia, ataxia, and dystonia.

BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.

Alzheimer’s disease affects more than 55 million people worldwide, and that figure is projected to nearly triple by 2050.